Therapeutic Asset Ratings

208 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Valproic Acid Solid Tumors	Miller Children's & Women's Hospital Long Beach	P1	CCC (49)
dc05f01 Solid Tumors	Heronova Pharmaceuticals	P1/2	CCC (49)
Tocilizumab Solid Tumors	Hoffmann-La Roche	P1/2	CCC (49)
Utomilumab Solid Tumors	Pfizer	P3	CCC (48)
Belvarafenib Solid Tumors	Hoffmann-La Roche	P2	CCC (48)
BMS-986504 Solid Tumors	Bristol-Myers Squibb	P2	CCC (48)
bnt324 Solid Tumors	DualityBio Inc.	P2	CCC (48)
bnt327 Solid Tumors	DualityBio Inc.	P2	CCC (48)
Brigimadlin Solid Tumors	Boehringer Ingelheim	P2	CCC (48)
Dapagliflozin Solid Tumors	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	P2	CCC (48)
Daraxonrasib Solid Tumors	Bristol-Myers Squibb	P2	CCC (48)
db-1305/bnt325 Solid Tumors	DualityBio Inc.	P2	CCC (48)
db-1311 Solid Tumors	DualityBio Inc.	P2	CCC (48)
Divarasib Solid Tumors	Hoffmann-La Roche	P2	CCC (48)
DOTATOC Solid Tumors	MedSIR	P2	CCC (48)
Eflapegrastim Solid Tumors	Spectrum Pharmaceuticals, Inc	P2	CCC (48)
Hrs-7058 Solid Tumors	Shandong Suncadia Medicine Co., Ltd.	P2	CCC (48)
Loratadine Solid Tumors	Val Adams	P2	CCC (48)
Pumitamig Solid Tumors	Bristol-Myers Squibb	P2	CCC (48)
Rain-32 Solid Tumors	Rain Oncology Inc	P2	CCC (48)
Telpegfilgrastim Solid Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (48)
Vebreltinib Solid Tumors	Apollomics Inc.	P2	CCC (48)
azd6244 Solid Tumors	Merck Sharp & Dohme LLC	P1	CCC (48)
Zofran Solid Tumors	UNC Lineberger Comprehensive Cancer Center	P1	CCC (48)
Sitravatinib Solid Tumors	Haider Mahdi	P2	CC (46)

Showing 51 to 75 of 208 assets